Peringatan Keamanan

During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day).

Anidulafungin

DB00362

biotech approved investigational

Deskripsi

Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 40-50 hours
Volume Distribusi * 30 to 50 L
Klirens (Clearance) * 1 L/h

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Hepatic metabolism of anidulafungin has not been observed. Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 (CYP450) isoenzymes. Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide that lacks antifungal activity.

Rute Eliminasi

Less than 1% of the administered radioactive dose was excreted in the urine. Anidulafungin is not hepatically metabolized.

Interaksi Obat

14 Data
Dicoumarol The therapeutic efficacy of Dicoumarol can be increased when used in combination with Anidulafungin.
Phenindione The therapeutic efficacy of Phenindione can be increased when used in combination with Anidulafungin.
Warfarin The therapeutic efficacy of Warfarin can be increased when used in combination with Anidulafungin.
Phenprocoumon The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Anidulafungin.
Acenocoumarol The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Anidulafungin.
4-hydroxycoumarin The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Anidulafungin.
Coumarin The therapeutic efficacy of Coumarin can be increased when used in combination with Anidulafungin.
(R)-warfarin The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Anidulafungin.
Ethyl biscoumacetate The therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Anidulafungin.
Fluindione The therapeutic efficacy of Fluindione can be increased when used in combination with Anidulafungin.
Clorindione The therapeutic efficacy of Clorindione can be increased when used in combination with Anidulafungin.
Diphenadione The therapeutic efficacy of Diphenadione can be increased when used in combination with Anidulafungin.
Tioclomarol The therapeutic efficacy of Tioclomarol can be increased when used in combination with Anidulafungin.
(S)-Warfarin The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Anidulafungin.

Target Protein

1,3-beta-glucan synthase component FKS1 fksA
1,3-beta-glucan synthase component GSC2 GSC2

Referensi & Sumber

Synthesis reference: Scott Jenkins, Gary Liversidge, Deborah Neville, "Nanoparticulate Anidulafungin Compositions and Methods for Making the Same." U.S. Patent US20090238867, issued September 24, 2009.
Artikel (PubMed)
  • PMID: 17316149
    Cappelletty D, Eiselstein-McKitrick K: The echinocandins. Pharmacotherapy. 2007 Mar;27(3):369-88.
  • PMID: 16117974
    Vazquez JA: Anidulafungin: a new echinocandin with a novel profile. Clin Ther. 2005 Jun;27(6):657-73.
  • PMID: 20606829
    Grover ND: Echinocandins: A ray of hope in antifungal drug therapy. Indian J Pharmacol. 2010 Feb;42(1):9-11. doi: 10.4103/0253-7613.62396.
  • PMID: 17044802
    Vazquez JA: The safety of anidulafungin. Expert Opin Drug Saf. 2006 Nov;5(6):751-8.
  • PMID: 19877741
    Menichetti F: Anidulafungin, a new echinocandin: effectiveness and tolerability. Drugs. 2009;69 Suppl 1:95-7. doi: 10.2165/11315570-000000000-00000.
  • PMID: 16779750
    Vazquez JA, Sobel JD: Anidulafungin: a novel echinocandin. Clin Infect Dis. 2006 Jul 15;43(2):215-22. Epub 2006 Jun 9.
  • PMID: 19113794
    Estes KE, Penzak SR, Calis KA, Walsh TJ: Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy. 2009 Jan;29(1):17-30. doi: 10.1592/phco.29.1.17.
  • PMID: 19877740
    Morace G, Borghi E, Iatta R, Montagna MT: Anidulafungin, a new echinocandin: in vitro activity. Drugs. 2009;69 Suppl 1:91-4. doi: 10.2165/11315560-000000000-00000.

Contoh Produk & Brand

Produk: 9 • International brands: 1
Produk
  • Ecalta
    Injection, powder, for solution • 100 mg • Intravenous • EU • Approved
  • Eraxis
    Kit • 50 mg/15mL • Intravenous • US • Approved
  • Eraxis
    Kit • 100 mg/30mL • Intravenous • US • Approved
  • Eraxis
    Injection, powder, lyophilized, for solution • 50 mg/15mL • Intravenous • US • Approved
  • Eraxis
    Injection, powder, lyophilized, for solution • 100 mg/30mL • Intravenous • US • Approved
  • Eraxis
    Powder, for solution • 100 mg / vial • Intravenous • Canada • Approved
  • Eraxis
    Powder, for solution • 100 mg / vial • Intravenous • Canada • Approved
  • Eraxis
    Injection, powder, lyophilized, for solution • 100 mg/30mL • Intravenous • US • Approved
Menampilkan 8 dari 9 produk.
International Brands
  • Ecalta — Pfizer

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul